| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
36,603 |
34,049 |
$1.39M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
44,760 |
41,264 |
$1.09M |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
5,174 |
4,913 |
$478K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
6,762 |
2,889 |
$142K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,809 |
1,726 |
$122K |
| 80346 |
|
7,642 |
7,538 |
$119K |
| 80361 |
|
7,645 |
7,537 |
$99K |
| 80364 |
|
6,597 |
6,504 |
$83K |
| 83992 |
|
7,639 |
7,534 |
$78K |
| 90837 |
Psychotherapy, 53 minutes with patient |
1,325 |
852 |
$78K |
| 80373 |
|
7,642 |
7,536 |
$77K |
| 80372 |
|
7,641 |
7,536 |
$76K |
| 80357 |
|
7,641 |
7,536 |
$76K |
| 80366 |
|
7,230 |
7,132 |
$71K |
| 80355 |
|
7,233 |
7,134 |
$71K |
| 80368 |
|
6,910 |
6,812 |
$70K |
| 80369 |
|
6,910 |
6,811 |
$68K |
| 80339 |
|
6,672 |
6,578 |
$66K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
1,320 |
1,282 |
$65K |
| 80354 |
|
7,647 |
7,541 |
$57K |
| 80348 |
|
7,650 |
7,540 |
$56K |
| 80356 |
|
7,646 |
7,540 |
$56K |
| 80353 |
|
7,645 |
7,540 |
$55K |
| 80324 |
|
7,647 |
7,541 |
$55K |
| 80358 |
|
7,651 |
7,543 |
$55K |
| 80349 |
|
7,640 |
7,535 |
$55K |
| 80359 |
|
7,641 |
7,536 |
$55K |
| 80305 |
|
7,522 |
7,091 |
$47K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
590 |
563 |
$45K |
| 20611 |
|
941 |
716 |
$45K |
| E0730 |
Transcutaneous electrical nerve stimulation (tens) device, four or more leads, for multiple nerve stimulation |
493 |
475 |
$37K |
| 80332 |
|
3,651 |
3,618 |
$36K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
1,914 |
886 |
$36K |
| 80345 |
|
3,255 |
3,227 |
$25K |
| 80350 |
|
3,255 |
3,227 |
$25K |
| 20553 |
|
785 |
707 |
$25K |
| 97161 |
|
527 |
487 |
$24K |
| 90838 |
|
437 |
419 |
$21K |
| 90791 |
Psychiatric diagnostic evaluation |
300 |
276 |
$20K |
| 27096 |
|
212 |
192 |
$20K |
| 80362 |
|
988 |
977 |
$19K |
| 62323 |
|
284 |
258 |
$18K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
734 |
730 |
$17K |
| 80365 |
|
988 |
977 |
$10K |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
1,503 |
1,404 |
$8K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
161 |
155 |
$7K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
503 |
255 |
$6K |
| 99215 |
Prolong outpt/office vis |
93 |
87 |
$4K |
| 80338 |
|
385 |
381 |
$4K |
| 80336 |
|
384 |
380 |
$4K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
129 |
126 |
$2K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
504 |
407 |
$1K |
| 99442 |
|
223 |
217 |
$1K |
| A4595 |
Electrical stimulator supplies, 2 lead, per month, (e.g., tens, nmes) |
50 |
50 |
$954.33 |
| 80320 |
|
72 |
72 |
$954.24 |
| 64493 |
|
13 |
13 |
$730.77 |
| 20610 |
|
27 |
24 |
$612.36 |
| 64494 |
|
13 |
13 |
$396.24 |
| J3490 |
Unclassified drugs |
195 |
114 |
$163.22 |
| 80335 |
|
385 |
381 |
$21.75 |
| S9452 |
Nutrition classes, non-physician provider, per session |
2,721 |
2,646 |
$13.12 |
| 99406 |
|
48 |
44 |
$0.11 |
| S9451 |
Exercise classes, non-physician provider, per session |
3,810 |
3,698 |
$0.00 |
| 1036F |
|
4,315 |
4,061 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
1,554 |
1,491 |
$0.00 |
| G8959 |
Clinician treating major depressive disorder communicates to clinician treating comorbid condition |
35 |
34 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
29 |
27 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
5,366 |
5,024 |
$0.00 |
| G8730 |
Pain assessment documented as positive using a standardized tool and a follow-up plan is documented |
10,522 |
9,791 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
2,317 |
1,904 |
$0.00 |
| 4004F |
|
2,746 |
2,602 |
$0.00 |
| S9449 |
Weight management classes, non-physician provider, per session |
2,708 |
2,635 |
$0.00 |
| G9622 |
Patient not identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method |
3,489 |
3,278 |
$0.00 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
40 |
39 |
$0.00 |